Tag: female infertility indusrty insights

Uncover key drivers, emerging technologies, and competitive movements shaping the female infertility market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Female Infertility Market covering 2026–2035?

The female infertility market has demonstrated steady growth over recent years. It is projected to expand from $1.86 billion in 2025 to $1.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.1%. Historically, this market expansion can be linked to trends like delayed childbearing, a heightened awareness of infertility, the widespread availability of fertility drugs, an increase in reproductive health clinics, and advancements in diagnostic imaging.

The female infertility market is projected to experience consistent expansion over the upcoming years, reaching a valuation of $2.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.8%. This anticipated growth during the forecast period is primarily driven by improvements in fertility drug development, the rise of individualized fertility care, greater use of AI for tracking fertility, the broadening scope of fertility tourism, and increasing capital directed towards reproductive health. Key developments expected during this timeframe involve a surge in demand for assisted reproductive technologies, a heightened emphasis on therapies addressing hormones and ovulation, the wider application of sophisticated diagnostic methods, the proliferation of fertility clinics and related services, and the incorporation of digital solutions into fertility management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Female Infertility Market?

The rising occurrence of infertility is projected to fuel expansion within the female infertility market moving ahead. This condition, infertility, is defined as the inability to achieve pregnancy following 12 months of consistent, unprotected intercourse. The escalation of infertility stems from various contributors, including postponed childbearing, shifts in lifestyle, exposure to environmental toxins, a surge in obesity rates, and elevated stress. Treatment for female infertility becomes necessary to confront and control fundamental medical, hormonal, or structural problems that hinder fertility, consequently improving the likelihood of conception and averting irreversible infertility. As an illustration, in April 2023, data from the World Health Organization, an intergovernmental entity situated in Switzerland, indicated that around 17.5% of adults worldwide, equating to roughly 1 in 6 people, experience infertility. Consequently, the growing frequency of infertility acts as a catalyst for the expansion of the female infertility market.

What Segments Are Identified Within The Structure Of The Female Infertility Market?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

Which Trends Are Influencing The Performance And Direction Of The Female Infertility Market?

Major companies operating in the female infertility market are concentrating on creating innovative products, such as non-invasive diagnostic tests, to gain a competitive edge. A non-invasive diagnostic test is a medical procedure designed to identify conditions or diseases without requiring surgery or body penetration. For example, in August 2024, Heranova Lifesciences, a US-based biotech firm, introduced an early access program for HerResolve, a non-invasive diagnostic test for endometriosis. Endometriosis impacts approximately 200 million women worldwide, causing symptoms including infertility, pain, and bleeding. For numerous women, an accurate diagnosis typically spans an average of 7-10 years from the onset of symptoms, primarily due to varied symptom presentation and the invasive nature of the most dependable diagnostic method, exploratory laparoscopic surgery. HerResolve aims to potentially shorten this diagnostic delay from years to months, leading to improved patient care and overall healthcare outcomes.

Which Leading Companies Dominate The Female Infertility Market Share?

Major companies operating in the female infertility market are Pfizer Inc, Merck And Co Inc, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Organon Theramex, Juniper Reproductive Health Ltd, Ferring Pharmaceuticals, Mankind Pharma, ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Merck KGaA, Gedeon Richter Plc, Novartis AG, AbbVie Inc, Ipsen, Theramex, Vitrolife AB, Conceivable Life Sciences, AIVF

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Female Infertility Market?

Europe was the largest region in the female infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Female Infertility Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

Browse Through More Reports Similar to the Global Female Infertility Market 2026, By The Business Research Company

Fertility Treatments Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Male Fertility Market Report 2026

https://www.thebusinessresearchcompany.com/report/male-fertility-global-market-report

Fertility Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Current Size And Growth Outlook For The Female Infertility Market?

In recent times, there has been a consistent upswing in the size of the female infertility market. The market is projected to increase from $1.79 billion in 2024 to $1.86 billion in 2025, indicative of a compound annual growth rate (CAGR) of 4.2%. Factors that have contributed to this growth curve in the historical period include an increasing trend of women opting to delay childbirth, lifestyle alterations, proactive government initiatives, a rising aging population, and the advanced prevalence of assisted reproductive technology (ART) treatment.

In the forthcoming years, the market size of female infertility will experience consistent growth. The market is projected to reach $2.18 billion in 2029, with a compound annual growth rate (CAGR) of 4.0%. This expansion in the prediction period is due to heightened awareness about fertility challenges, an escalation in the occurrence of polycystic ovary syndrome, increased cases of uterine irregularities, and a rise in genetic abnormalities incidences, as well as growing obesity. Trends anticipated within this forecast period encompass advancements in preimplantation genetic examination, technological progression, novel diagnostic technologies, fertility preservation, and the use of telemedicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

What Growth-Enabling Forces Are Impacting The Female Infertility Market?

The female infertility market is anticipated to grow due to the escalating incidence of infertility. Infertility is defined as the inability to become pregnant after a year of regular unprotected sexual activity. This rise in infertility can be attributed to factors such as delayed childbearing, modifications in lifestyle, environmental pollutants, increasing obesity, and heightened stress levels. Female infertility treatment is necessary to identify and manage medical, hormonal or structural problems that hinder fertility, thus improving the likelihood of pregnancy and avoiding enduring infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a public body in the UK under the umbrella of the Department of Health and Social Care, reported that licensed fertility clinics in the UK conducted nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. Over 90% of these treatments were done with a partner, involving around 100,000 individuals. Hence, the escalating incidence of infertility is positively impacting the growth of the female infertility market.

How Does The Female Infertility Market Differ By Segment?

The female infertilitymarket covered in this report is segmented –

1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine

2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations

3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine

What New Opportunities Are Emerging From Trends In The Female Infertility Market?

Leading companies in the female infertility market are directing their efforts towards the creation of novel products like non-invasive diagnostic tests as a strategic move to stay competitive in the sector. Non-invasive diagnostic tests, which identify conditions or illnesses without the necessity for surgery or penetration of the body, form an innovative solution. For example, Heranova Lifesciences, an American biotech firm, rolled out an early access program for HerResolve, their proprietary non-invasive diagnostic test for endometriosis in August 2024. With endometriosis impacting nearly 200 million women globally and resulting in infertility, pain, and bleeding; accurate diagnosis can typically take between 7-10 years from when the symptoms first appear. This is primarily due to the diversity of symptom manifestation and the invasive nature of the most dependable diagnostic tool – exploratory laparoscopic surgery. However, HerResolve could potentially shorten this process from years to just a few months, thereby enhancing both the patient’s health journey and healthcare results dramatically.

Who Are The Most Influential Companies In The Female Infertility Market?

Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

Which Region Is Leading Innovation In The Female Infertility Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

Browse Through More Reports Similar to the Global Female Infertility Market 2025, By The Business Research Company

Female Fertility And Pregnancy Rapid Test Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/female-fertility-and-pregnancy-rapid-test-global-market-report

Pregnancy Test Kits Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pregnancy-test-kits-global-market-report

Assisted Reproductive Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/assisted-reproductive-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Female Infertility Market, and What Factors Will Drive It?

The market size for female infertility has seen continual growth over recent years. The forecast for growth shows an increase from $1.79 billion in 2024 to $1.86 billion in 2025, with a compound annual growth rate (CAGR) of 4.2%. The growth observed in the historic period can be credited to an increasing trend of women choosing to have children later in life, emerging changes in lifestyle, amplified government programs, an escalating aging population, and increased utilization of assisted reproductive technology (ART) treatment.

The market size for female infertility, in the upcoming years, is predicted to witness continuous augmentation, reaching $2.18 billion by 2029, with a compound annual growth rate (CAGR) of 4.0%. This projected growth through the forecast period can be accredited to the escalating consciousness about fertility complications, uptick in instances of polycystic ovary syndrome, rising number of uterine anomalies, increasing occurrence of genetic ailments, and growing obesity. Key trends in the forecast span are anticipated to be the progress in preimplantation genetic testing, technological evolution, innovative diagnostic technologies, fertility conservation, and the rise of telemedicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theFemale Infertility Market?

The rise in cases of infertility is projected to fuel the expansion of the female infertility market. Infertility is characterized as the incapability to get pregnant despite having regular, unprotected sexual intercourse for 12 months. The surge in infertility numbers can be attributed to late pregnancies, alterations in lifestyle, contamination in the environment, a growing number of obesity cases, and heightened stress levels. To manage infertility effectively, it’s necessary to address hormonal, medical, or structural problems that might be impacting fertility, thus increasing the probability of pregnancy and protecting against permanent infertility. For instance, the Human Fertilization and Embryology Authority, a UK’s non-departmental public entity of the Department of Health and Social Care, reported in July 2024 that fertility clinics in the UK licensed by it carried out close to 77,000 fresh and frozen embryo transfer IVF cycles for about 52,500 patients in 2022. More than 90% of these patients underwent treatment with a partner, involving nearly 100,000 individuals. Consequently, the rise in infertility instances accelerates the expansion of the female infertility market.

Which Segments in the Female Infertility Offer the Most Growth?

The female infertilitymarket covered in this report is segmented –

1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine

2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations

3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theFemale Infertility Market?# Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Female Infertility Industry?

Leading enterprises in the female infertility market are concentrating on the creation of novel products, such as non-invasive diagnostic examinations, to gain a competitive industry advantage. A non-invasive diagnostic examination is a form of medical testing used to identify conditions or diseases without the need for surgical procedures or body penetration. For example, in August 2024, Heranova Lifesciences, a biotech firm based in the United States, introduced an early access program for HerResolve, a non-invasive diagnostic examination for endometriosis. Endometriosis, which affects roughly 200 million women globally, can cause infertility, pain, and bleeding. An accurate diagnosis for many of these women takes between 7-10 years on average from the time symptoms first appear due to a varied symptom display and the invasive element of the most dependable diagnostic tool, exploratory laparoscopic surgery. HerResolve could potentially shorten this diagnostic period from years to months, resulting in improved patient and healthcare results. The primary aim of HerResolve is to considerably reduce this time frame, therefore enhancing medical care and results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What Are the Key Elements That Define the Female Infertility Market?

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to carry a pregnancy to term. It is a complex condition resulting from various factors affecting the reproductive system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Female Infertility Market Growth in 2025?

In recent times, there has been consistent growth in the market size of female infertility. From $1.79 billion in 2024, it is projected to increase to $1.87 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. The expansion during the historic period can be associated with the rising trend of delayed childbirth among women, shifts in lifestyle patterns, the implementation of more government initiatives, the upturn in the aging demographics, and the heightened use of assisted reproductive technology (ART) treatments.

What Is the Forecast for the Female Infertility Market Size Through 2029?

Predictions suggest a consistent increase in the size of the female infertility market in the forthcoming years. The market is projected to expand to $2.19 billion by 2029, with a compound annual growth rate (CAGR) of 4.1%. The surge during the forecast period can be associated with growing consciousness surrounding fertility problems, escalating instances of polycystic ovary syndrome and uterine abnormalities, increase in genetic disorders, and a rise in obesity. Key trends for the period include the progression in preimplantation genetic testing, technological evolution, innovative diagnostic technologies, preservation of fertility, and the rise of telemedicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

What are the Key Market Players in Female Infertility Market and How They’re Evolving?

Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

What Are the Primary Growth Drivers in the Female Infertility Market?

The escalating incidence of infertility is projected to fuel the expansion of the female infertility market in the future. Infertility represents the incapacity to conceive after a year of regular, unprotected sexual activity. This growing infertility is spurred by elements like deferred child-bearing, alterations in lifestyle, environmental pollutants, increased obesity, and elevated stress levels. Female infertility treatments are necessary to tackle and manage underlining medical, hormonal, or structural problems that harm fertility, thereby increasing the likelihood of conception and averting permanent infertility. For example, in July 2024, as per the Human Fertilization and Embryology Authority, a non-departmental public body in the UK under the Department of Health and Social Care, licensed fertility clinics in the UK administered almost 77,000 fresh and frozen embryo transfer IVF cycles to 52,500 patients in 2022. More than 90% of these patients underwent treatment with a partner, involving about 100,000 individuals. Consequently, the escalating incidence of infertility propels the expansion of the female infertility market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

What Are the Leading Segments in the Global Female Infertility Industry?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

What Are the Key Market Trends in the Female Infertility Industry?

Top players in the female infertility industry are directing their efforts towards creating breakthrough products such as non-invasive diagnostic tests that can provide them with a competitive boost. A non-invasive diagnostic test is a type of medical examination that identifies diseases or conditions without the need for surgery or intrusion into the body. For instance, in August of 2024, Heranova Lifesciences, a biotech organization based in the United States, initiated an early access scheme for HerResolve, a non-invasive diagnostic examination for endometriosis. Endometriosis affects approximately 200 million women globally, leading to issues like infertility, discomfort, and unexpected bleeding. It can take on average between 7-10 years for women to receive a correct diagnosis after symptom onset, primarily due to diverse symptom representation and the invasive nature of the most reliable diagnostic technique, exploratory laparoscopic surgery. HerResolve holds the potential to trim down this delay in diagnosis from years to months, thereby enhancing both patient and healthcare results. Through HerResolve, the goal is to considerably lessen this diagnostic timeframe, thus enhancing patient management and results.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What Is the Regional Outlook for the Female Infertility Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

This Report Delivers Insight On:

1. How big is the female infertility market, and how is it changing globally?

2. Who are the major companies in the female infertility market, and how are they performing?

3. What are the key opportunities and risks in the female infertility market right now?

4. Which products or customer segments are growing the most in the female infertility market?

5. What factors are helping or slowing down the growth of the female infertility market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What is the Anticipated CAGR of the Female Infertility Market, and What Factors Will Drive It?

The market for female infertility has seen a consistent expansion in recent years. The valuation is expected to rise from $1.79 billion in 2024 to $1.87 billion in 2025, registering a compound annual growth rate (CAGR) of 4.5%. The augmentation during the historical period can be credited to a range of factors including the emerging trend of women postponing having children, lifestyle alterations, proliferating government initiatives, an increasing elderly population, and the surge in assisted reproductive technology (ART) practices.

The market size of female infertility is predicted to undergo consistent expansion in the upcoming years. By 2029, it is expected to reach $2.19 billion, with a compound annual growth rate (CAGR) of 4.1%. The growth in this forecast period is attributable to an enhanced understanding of fertility problems, an uptick in instances of polycystic ovary syndrome, an increase in cases of uterine abnormalities, a surge in occurrences of genetic disorders, and rising obesity. Key trends observed in this forecast period include advancements in preimplantation genetic screening, technological progression, emerging diagnostic technologies, fertility retention, and telemedicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Which Factors and External Forces Are Driving Demand in the Female Infertility Market?

The upward trend in infertility is projected to fuel the expansion of the female infertility market in the future. Infertility is defined as the inability to conceive following 12 months of regular, unprotected sexual activity. This escalating problem is prompted by various factors including delaying childbearing, alterations in lifestyle, environmental contaminants, rising obesity levels, and augmented stress levels. Treatment for female infertility is essential to address and manage the root causes like medical, hormonal, or structural problems that hinder fertility, thereby improving the likelihood of conception and averting permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based independent public body of the Department of Health and Social Care, reported that licensed fertility clinics across the UK conducted around 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. Over 90% of these patients pursued treatment with a partner, involving nearly 100,000 individuals. Therefore, the rise in infertility prevalence underpins the growth of the female infertility market.

Which Segments in the Female Infertility Offer the Most Growth?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

What Are the Fastest-Growing Geographies in the Female Infertility Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Female Infertility Market?

Leading businesses in the female infertility market are prioritizing the creation of novel products such as non-invasive diagnostic tests to establish their prominence within the sector. Non-invasive diagnostic tests are medical procedures that allow for disease or condition detection without the need for surgical intervention or bodily penetration. For example, in August 2024, Heranova Lifesciences, a biotech firm headquartered in the US, initiated an early access scheme for HerResolve, a non-invasive diagnostic examination for endometriosis – a condition impacting around 200 million women globally. This disease often results in infertility, pain, and bleeding. Unfortunately, a majority of women receive a definitive diagnosis only 7-10 years after initial symptom presentation, a delay primarily attributable to symptom inconsistency and the invasive nature of the most trusted diagnostic approach, exploratory laparoscopic surgery. HerResolve aims to considerably lessen this diagnostic time gap, transitioning it from years to mere months, thereby enhancing both patient and healthcare results. Its significant goal is to media this lengthy process to ensure improved patient care and outcome.

View the full report here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What Are the Key Elements That Define the Female Infertility Market?

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to carry a pregnancy to term. It is a complex condition resulting from various factors affecting the reproductive system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model